R Scripts for Pediatric AML Minimal Residual Disease Prognostic Analysis

The TARGET-AML initiative provided data for a retrospective cohort study of 1,205 pediatric patients with acute myeloid leukemia treated across Children's Oncology Group clinical trial centers between 1996 and 2016. Xiong-yu Liao authored this collection of R scripts, which analyze the prognostic performance of different minimal residual disease thresholds for 5-year event-free survival. The analysis includes Kaplan-Meier estimates, Cox proportional hazards models, ROC curves, and net reclassification improvement.

Use Cases

• Reproduce survival analysis and hazard ratio calculations based on MRD thresholds described in the study
• Apply receiver operating characteristic (ROC) curve analysis to determine optimal prognostic thresholds for clinical outcomes
• Calculate net reclassification improvement (NRI) to compare the performance of different risk classification models
• Conduct Kaplan-Meier survival estimation for event-free survival in a pediatric AML cohort

Strengths

• Analysis is based on a specific cohort of 1,205 pediatric patients
• Study includes a median follow-up period of 6.2 years (range 0.5–20.1 years)
• Scripts implement multiple statistical methods: Kaplan-Meier, Cox models, ROC, and NRI

Limitations

• Row count for the underlying data is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The retrospective design using historical trial data may limit generalizability to contemporary treatments, as noted in the description

Provenance

Source

Therapeutically Applicable Research to Generate Effective Treatments (TARGET)-AML initiative and Children's Oncology Group (COG) clinical trials

Collection Method

Retrospective cohort study using clinical trial data

Time Range

Patients enrolled between September 1996 and December 2016

Freshness

Last updated 2026-05-08 17:28:01; freshness should be verified

Geography

Patients treated across Children's Oncology Group clinical trial centers; specific geography not stated